These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 22942726)

  • 1. Role of prion protein aggregation in neurotoxicity.
    Corsaro A; Thellung S; Villa V; Nizzari M; Florio T
    Int J Mol Sci; 2012; 13(7):8648-8669. PubMed ID: 22942726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Unexposed Secrets of Prion Protein Oligomers.
    Wang G; Wang M; Li C
    J Mol Neurosci; 2015 Aug; 56(4):932-937. PubMed ID: 25823438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of misfolding of the human prion protein revealed by a pathological mutation.
    Sanz-Hernández M; Barritt JD; Sobek J; Hornemann S; Aguzzi A; De Simone A
    Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33731477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prion Concept and Synthetic Prions.
    Legname G; Moda F
    Prog Mol Biol Transl Sci; 2017; 150():147-156. PubMed ID: 28838659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers.
    Ugalde CL; Finkelstein DI; Lawson VA; Hill AF
    J Neurochem; 2016 Oct; 139(2):162-180. PubMed ID: 27529376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic prions and other human neurodegenerative proteinopathies.
    Le NT; Narkiewicz J; Aulić S; Salzano G; Tran HT; Scaini D; Moda F; Giachin G; Legname G
    Virus Res; 2015 Sep; 207():25-37. PubMed ID: 25449570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prion and prion-like diseases in animals.
    Aguilar-Calvo P; García C; Espinosa JC; Andreoletti O; Torres JM
    Virus Res; 2015 Sep; 207():82-93. PubMed ID: 25444937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prion neurotoxicity: insights from prion protein mutants.
    Solomon IH; Schepker JA; Harris DA
    Curr Issues Mol Biol; 2010; 12(2):51-61. PubMed ID: 19767650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenic mutations within the hydrophobic domain of the prion protein lead to the formation of protease-sensitive prion species with increased lethality.
    Coleman BM; Harrison CF; Guo B; Masters CL; Barnham KJ; Lawson VA; Hill AF
    J Virol; 2014 Mar; 88(5):2690-703. PubMed ID: 24352465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human prion protein fragment 90-231, a useful model to study prion neurotoxicity.
    Corsaro A; Thellung S; Villa V; Nizzari M; Aceto A; Florio T
    OMICS; 2012; 16(1-2):50-9. PubMed ID: 22321015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prion-Like Characteristics of Polyglutamine-Containing Proteins.
    Pearce MMP; Kopito RR
    Cold Spring Harb Perspect Med; 2018 Feb; 8(2):. PubMed ID: 28096245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular aspects of prion replication in vitro.
    Grassmann A; Wolf H; Hofmann J; Graham J; Vorberg I
    Viruses; 2013 Jan; 5(1):374-405. PubMed ID: 23340381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The engineered peptide construct NCAM1-Aβ inhibits fibrillization of the human prion protein (PrP).
    Gielnik M; Zhukova L; Zhukov I; Gräslund A; Kozak M; Wärmländer S
    Acta Biochim Pol; 2022 Feb; 69(1):257-261. PubMed ID: 35143147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prion protein glycans reduce intracerebral fibril formation and spongiosis in prion disease.
    Sevillano AM; Aguilar-Calvo P; Kurt TD; Lawrence JA; Soldau K; Nam TH; Schumann T; Pizzo DP; Nyström S; Choudhury B; Altmeppen H; Esko JD; Glatzel M; Nilsson KPR; Sigurdson CJ
    J Clin Invest; 2020 Mar; 130(3):1350-1362. PubMed ID: 31985492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PrP P102L and Nearby Lysine Mutations Promote Spontaneous
    Kraus A; Raymond GJ; Race B; Campbell KJ; Hughson AG; Anson KJ; Raymond LD; Caughey B
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prions: protein aggregation and infectious diseases.
    Aguzzi A; Calella AM
    Physiol Rev; 2009 Oct; 89(4):1105-52. PubMed ID: 19789378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prion protein interconversions and the transmissible spongiform encephalopathies.
    Horiuchi M; Caughey B
    Structure; 1999 Oct; 7(10):R231-40. PubMed ID: 10545332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generalizing a mathematical model of prion aggregation allows strain coexistence and co-stability by including a novel misfolded species.
    Lemarre P; Pujo-Menjouet L; Sindi SS
    J Math Biol; 2019 Jan; 78(1-2):465-495. PubMed ID: 30116882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective processing and metabolism of disease-causing mutant prion proteins.
    Ashok A; Hegde RS
    PLoS Pathog; 2009 Jun; 5(6):e1000479. PubMed ID: 19543376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of infective property of recombinant prion protein amyloids in cultured cells overexpressing cellular prion protein.
    Kim DH; Lee HM; Ryou C
    J Korean Med Sci; 2014 Dec; 29(12):1604-9. PubMed ID: 25469058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.